REPORT.

SEC. 508. REPORT.(a) In General.—Not later than four years after the date of enactment of this Act and every five years thereafter, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and make publicly available, including through posting on the Internet Web site of the Food and Drug Administration, a report on the 126 STAT. 1046 implementation of sections 505A and 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a, 355c).(b) Contents.—Each report under subsection (a) shall include—(1) an assessment of the effectiveness of sections 505A and 505B of the Federal Food, Drug, and Cosmetic Act in improving information about pediatric uses for approved drugs and biological products, including the number and type of labeling changes made since the date of enactment of this Act and the importance of such uses in the improvement of the health of children;(2) the number of required studies under such section 505B that have not met the initial deadline provided under such section 505B, including—(A) the number of deferrals and deferral extensions granted and the reasons such extensions were granted;(B) the number of waivers and partial waivers granted; and(C) the number of letters issued under subsection (d) of such section 505B;(3) an assessment of the timeliness and effectiveness of pediatric study planning since the date of enactment of this Act, including the number of initial pediatric study plans not submitted in accordance with the requirements of subsection (e) of such section 505B and any resulting rulemaking;(4) the number of written requests issued, accepted, and declined under such section 505A since the date of enactment of this Act, and a listing of any important gaps in pediatric information as a result of such declined requests;(5) a description and current status of referrals made under subsection (n) of such section 505A;(6) an assessment of the effectiveness of studying biological products in pediatric populations under such sections 505A and 505B and section 409I of the Public Health Service Act (42 U.S.C. 284m);(7)(A) the efforts made by the Secretary to increase the number of studies conducted in the neonatal population (including efforts made to encourage the conduct of appropriate studies in neonates by companies with products that have sufficient safety and other information to make the conduct of the studies ethical and safe); and(B) the results of such efforts;(8)(A) the number and importance of drugs and biological products for children with cancer that are being tested as a result of the programs under such sections 505A and 505B and under section 409I of the Public Health Service Act; and(B) any recommendations for modifications to such programs that would lead to new and better therapies for children with cancer, including a detailed rationale for each recommendation;(9) any recommendations for modification to such programs that would improve pediatric drug research and increase pediatric labeling of drugs and biological products;(10) an assessment of the successes of and limitations to studying drugs for rare diseases under such sections 505A and 505B; and126 STAT. 1047(11) an assessment of the Secretary’s efforts to address the suggestions and options described in any prior report issued by the Comptroller General, Institute of Medicine, or the Secretary, and any subsequent reports, including recommendations therein, regarding the topics addressed in the reports under this section, including with respect to—(A) improving public access to information from pediatric studies conducted under such sections 505A and 505B; and(B) improving the timeliness of pediatric studies and pediatric study planning under such sections 505A and 505B.(c) Stakeholder Comment.—At least 180 days prior to the submission of each report under subsection (a), the Secretary shall consult with representatives of patient groups (including pediatric patient groups), consumer groups, regulated industry, academia, and other interested parties to obtain any recommendations or information relevant to the report including suggestions for modifications that would improve pediatric drug research and pediatric labeling of drugs and biological products.